PLEASE NOTE THE PROGRAM BEGINS ON FRIDAY MORNING, JANUARY 18, 2019

17th Oncology Update: Advances and Controversies
Breckenridge, Colorado
January 18-21, 2019

Friday, January 18, 2019

Registration: Begins at 6:30 am

6:50 am
Welcome Remarks
Merrick I. Ross, MD

Session I
7:00 am-8:15am – Prevention and Screening
Moderator: Merrick I. Ross, MD

Results of Lung Cancer Screening: Have Improved Outcomes Been Realized?
Jeremy J. Erasmus, MD

Melanoma Primary Prevention Initiatives: Education and Legislation*
Jeffrey E. Gershenwald, MD

HPV Vaccination: Penetration, Efficacy, and Expanding the Indications*
Kathleen M. Schmeler, MD

Anal Cancer: Etiology, Epidemiology, and Prevention
Craig A. Messick, MD

Panel Q & A
Session II
8:15 am-9:30 am – Outcomes and Palliative Care
Moderator: Brian D. Badgwell, MD

Patient Reported Outcomes: Does This Improve the Patient Care Experience?*
Thomas A. Aloia, MD

Integrating Cancer Care Quality Into National Public Reporting and Pay-for-Performance Programs*
Karl Y. Bilimoria, MD

Early Integration of the Palliative Care Team: Impact on Outcomes*
Sririan Yennu, MD

Palliative Surgery: How to Measure Success*
Brian D. Badgwell, MD

Panel Q & A

10:00 am – Noon – Meet the Professor

Session III
5:00 pm-8:30 pm – Plenary Session
Moderator: Merrick I. Ross, MD

PD-1 Resistance: Definitions, Frequency, and Biomarkers
Hussein A. Tawbi, MD

Oncolytic(intralesional) Immunotherapy: Can We Make a “Cold” Tumor “Hot”?
Robert H. Andtbacka, MD

Checkpoint Blockade and XRT: What is the Evidence for Synergism and an “Abscopal” Effect?
James W. Welch, MD

The Role of the Microbiome in the Response to Immunotherapy: The “Scoop is in the Poop”
Jennifer Wargo, MD

The Potential Role of CAR-T Therapy in Solid Tumors
TBD
Promising Actionable Biomarkers From Phase I Studies
Funda Meric-Bernstam, MD

Novel Nanoparticle Technology to Detect Micrometastatic Disease
Charles M. Balch, MD

Diagnosis and Management of Treatment-related Toxicities
  Immune-related Toxicities
  Isabella C. Glitza, MD

  Lymphedema
  Edward I. Chang, MD

  Graft vs Host Disease of the Eye
  Stella K. Kim, MD

Welcome Reception: 8:30-9:30 pm

Saturday, January 19, 2019

Session IV
  7:30 am-9:30 am – Thoracic Oncology
  Moderator: Stephen G. Swisher, MD

  Evolving Front-line Therapy for Stage 3 MSCLC: Results of the Pacific Trial
  James W. Welch, MD

  Advances in the Treatment of Metastatic NSCLC
  John V. Heymach, MD

  Survival Outcomes for Local therapy of Oligo-metastatic NSCLC:
  Surgery or Radiation Therapy?
  Stephen G. Swisher, MD

  New Paradigm in the Treatment of Small-Cell Lung Cancer
  Quynh Nguyen, MD

  Chemo-radiation for Advanced Esophageal Cancer:
  Front-line Results and the Role if Any for Salvage Surgery
  Wayne L. Hofstetter, MD
Panel Q and A

Case Presentations
Moderator: Stephen G. Swisher, MD

10:00 am-Noon - Meet the Professor

Session V
4:30 pm-7:30 pm – Breast and Gynecological Cancer
Moderator: Kelly K. Hunt, MD

Novel Approaches to the Axilla in Node Positive Breast Cancer After Neo-adjuvant Therapy
Kelly K. Hunt, MD

Results From the Taylor Rx Trial: Impact on Clinical Practice
Mariana Chavez-McGregor, MD

Neo-adjuvant Therapy for Node Positive/ER Positive Breast Cancer: Hormone vs Chemotherapy?
TBD

Adjuvant Radiation Therapy for Breast Cancer: Current Controversies
Thomas Buchholz, MD

Advances in the Treatment of Her-2 Positive Breast Cancer
Mariana Chavez-McGregor, MD

Immunotherapy for Breast Cancer: Is Progress Finally Being Made?
Elizabeth A. Mittendorf, MD

BRCA as a Biomarker for PARP Inhibition in Breast and Ovarian Cancer?
Jennifer K. Litton, MD

Value of Establishing a Tumor Registry for Rare Gynecological Malignancies
Michael M. Frumovitz, MD

Panel Q & A

Case Presentations
Moderator: Rosa F. Hwang, MD
Panel: All Speakers
Sunday, January 20, 2019
Session VI
7:00 am-9:30 am - Urology
Moderator: Christopher G. Wood, MD

Making the Case for Treating Primary Prostate Cancer

Robotic Prostatectomy
John W. Davis, MD

External Beam Radiation
Andrew K. Lee, MD

MRI Guided Brachytherapy
Steven J. Frank, MD

Surveillance
TBD

Advances in Systemic therapy for Aggressive Variant Prostate Cancer
Ana Aparicio, MD

Does Control of the Primary Tumor Improve Outcomes in Metastatic GU Cancers?

Prostate Cancer
Brian F. Chapin, MD

Renal Cell
Christopher G. Wood, MD

Novel Strategies in the Treatment of Disseminated Renal Cell Cancer
TBD

Panel Q & A

Case Presentations
Moderator: Christopher G. Wood, MD
Panelists: All Speakers; Neema Navai, MD

10:00 am-Noon - Meet the Professor
**Session VII**

*4:30 pm - 7:30 pm – GI Oncology*

**Moderator:** Robert A. Wolff, MD

**New Neo-Adjuvant Approaches for Resectable Pancreas Cancer**
TBD

**Definitive Radiation Therapy for Hepatobiliarys Cancer: Can This Replace Surgical Resection?**
Christopher Crane, MD

**Molecular Biomarker Based Therapy for Colorectal Cancer: A New Standard of Care?**
TBD

**Evolving Strategies in the Treatment of Young-Age Colon Cancer**
Y. Nancy You, MD

**Can We Apply Lessons Learned in Rectal Cancer to Improve the Surgical Outcomes in Colon Cancer**
Brian K. Bednarski, MD

**The Evolving Role of HIPEC in Gastric Cancer**
Brian D. Badgwell, MD

**Advances in the Systemic Therapy of Gastric Cancer**
TBD

**Panel Q & A**

**Case Presentations**
Moderator: Robert A. Wolff, MD
Panel: All Speakers
Monday, January 21, 2019

Session VIII
7:00 am-10:30 am – Cutaneous Oncology
Moderator: Merrick I. Ross, MD

Completion Dissection in Melanoma Patients With a Positive Sentinel Node:
Is the Controversy Finally Resolved?
Merrick I. Ross, MD

Adjuvant and Neo-adjuvant Therapy: Which Patients? What Therapy?
Hussein A. Tawbi, MD

Front-line Therapy for Disseminated Melanoma:
Current Standards and Future Directions
Michael A. Davies, MD, PhD

New Paradigm in the Treatment of Melanoma Brain Metastases:
Are We Finally Making Progress?
Michael A. Davies, MD, PhD

Targeted and Immunotherapy for Advanced Non-melanoma Skin Cancer
Michael R. Migden, MD

ADJOURNMENT

*Presentations are appropriate for ethics credit